share_log

Vertex Pharmaceuticals | 8-K: Vertex Reports Second Quarter 2024 Financial Results

Vertex Pharmaceuticals | 8-K: Vertex Reports Second Quarter 2024 Financial Results

福泰制药 | 8-K：Vertex 公布 2024 年第二季度财务业绩
美股SEC公告 ·  2024/08/01 16:07

Moomoo AI 已提取核心信息

Vertex Pharmaceuticals reported Q2 2024 product revenues of $2.65 billion, up 6% YoY, driven by strong TRIKAFTA/KAFTRIO performance. The company raised its full-year 2024 product revenue guidance to $10.65-$10.85 billion. Combined GAAP R&D and SG&A expenses were $1.3 billion, while acquired IPR&D expenses reached $4.4 billion due to the Alpine Immune Sciences acquisition.The FDA granted Priority Review for two key products: the vanzacaftor triple combination therapy for cystic fibrosis with a PDUFA date of January 2, 2025, and suzetrigine for moderate-to-severe acute pain with a PDUFA date of January 30, 2025. The company has also received validation of vanzacaftor triple MAA submissions in the EU and UK.Vertex continues to advance its broad pipeline, including CASGEVY launches for SCD and TDT with over 35 authorized treatment centers activated globally. The company reported strong cash position of $10.2 billion as of June 30, 2024, despite the Alpine acquisition impact. Multiple clinical milestones are expected in H2 2024 across various programs including pain, kidney diseases, and type 1 diabetes.
Vertex Pharmaceuticals reported Q2 2024 product revenues of $2.65 billion, up 6% YoY, driven by strong TRIKAFTA/KAFTRIO performance. The company raised its full-year 2024 product revenue guidance to $10.65-$10.85 billion. Combined GAAP R&D and SG&A expenses were $1.3 billion, while acquired IPR&D expenses reached $4.4 billion due to the Alpine Immune Sciences acquisition.The FDA granted Priority Review for two key products: the vanzacaftor triple combination therapy for cystic fibrosis with a PDUFA date of January 2, 2025, and suzetrigine for moderate-to-severe acute pain with a PDUFA date of January 30, 2025. The company has also received validation of vanzacaftor triple MAA submissions in the EU and UK.Vertex continues to advance its broad pipeline, including CASGEVY launches for SCD and TDT with over 35 authorized treatment centers activated globally. The company reported strong cash position of $10.2 billion as of June 30, 2024, despite the Alpine acquisition impact. Multiple clinical milestones are expected in H2 2024 across various programs including pain, kidney diseases, and type 1 diabetes.
福泰制药报告2024年第二季度产品营业收入为26.5亿美金，同比增长6%，主要受益于TRIKAFTA/KAFTRIO的强劲表现。公司将2024年全年产品营业收入的指导提高至106.5亿-108.5亿美金。综合GAAP研发和销售、管理费用为13亿美金，同时由于收购Alpine Immune Sciences，获得的知识产权研发费用达到44亿美金。FDA对两个关键产品给予优先审评：用于囊性纤维化的vanzaftor三重组合疗法，其PDUFA日期为2025年1月2日，以及用于中度至重度急性疼痛的suzetrigine，其PDUFA日期为2025年1月30日。公司还获得了EU和英国vanzaftor三...展开全部
福泰制药报告2024年第二季度产品营业收入为26.5亿美金，同比增长6%，主要受益于TRIKAFTA/KAFTRIO的强劲表现。公司将2024年全年产品营业收入的指导提高至106.5亿-108.5亿美金。综合GAAP研发和销售、管理费用为13亿美金，同时由于收购Alpine Immune Sciences，获得的知识产权研发费用达到44亿美金。FDA对两个关键产品给予优先审评：用于囊性纤维化的vanzaftor三重组合疗法，其PDUFA日期为2025年1月2日，以及用于中度至重度急性疼痛的suzetrigine，其PDUFA日期为2025年1月30日。公司还获得了EU和英国vanzaftor三重MAA提交的验证。福泰继续推进其广泛的管线，包括为SCD和TDt推出的CASGEVY，在全球激活了超过35个授权治疗中心。尽管受到Alpine收购的影响，公司截至2024年6月30日报告的现金状况强劲，达到了102亿美金。预计在2024年下半年将有多个临床里程碑在包括疼痛、肾脏疾病和1型糖尿病等多个项目中实现。

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息

    热门市场机会

    市场热议龙头榜 市场热议龙头榜
    序号 代码 最新价
    特斯拉
    TSLA
    274.571
    英伟达
    NVDA
    108.950
    Gorilla Technology
    GRRR
    25.760
    4
    Newsmax
    NMAX
    170.000
    5
    Palantir
    PLTR
    83.680
    解锁完整榜单
    立即解锁

    热门讨论

    中概股财报季火热：惊喜盈利能否延续涨势？
    1. 哪些行业可能成为本轮中概股财报季的市场焦点？ 2. 在政府强调科技创新和可持续发展的背景下，你认为哪些行业具有最大的增长潜力？ 展开
    中国两会：会议前后股票价格走势的主要要点

    热门讨论

    FOMC维持利率但不确定性高企：美股后市走向如何？
    🎙️讨论 1. 美联储强调政策路径存在“高度不确定性”，你更关注利率预期变化还是经济数据对市场的短期影响？ 2. 若核心通胀维持高位，哪类板块更具交易机会——防御型股票还是科技成长股？ 展开
    联邦公开市场委员会新闻发布会，2025年3月19日

    - 没有更多了 -